Phaseline

Targets › ACVR1

ACVR1 (Activin receptor type-1): drug programs, companies and trials

3 programs from 3 companies in 25 trials: 15 Phase 2, 9 Phase 1, 1 Phase 3; Oncology, Hematology, Immunology; next expected readout Dec 2026.

Bone morphogenetic protein (BMP) type I receptor that is involved in a wide variety of biological processes, including bone, heart, cartilage, nervous, and reproductive system development and regulation. As a type I receptor, forms heterotetrameric receptor complexes with the type II receptors AMHR2, ACVR2A or ACVR2B. Upon binding of ligands such as BMP7 or GDF2/BMP9 to the heteromeric complexes, type II receptors…. (UniProt, Q04771)

Open in Phaseline: the race on ACVR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Swedish Orphan BiovitrumPacritinib
Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor
JAK2, FLT3, ACVR1, IRAK1Phase 3Primary Myelofibrosis; VEXAS; Myelofibrosis; Acute Myeloid Leukemia …Dec 2026
GSKMomelotinib
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Activin receptor type-1 inhibitor
JAK1, JAK2, ACVR1Phase 2Primary Myelofibrosis; Myelodysplastic Syndromes; VEXAS Syndome; Myeloid Leukemia …Dec 2026
TheradexPacritinib
Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor
JAK2, FLT3, ACVR1, IRAK1Phase 2Leukemia, Myelomonocytic, ChronicJul 2028

Conditions

Primary Myelofibrosis (4) Myelofibrosis (3) Myelodysplastic Syndromes (2) VEXAS Syndome (1) Myeloid Leukemia (1) VEXAS (1) Acute Myeloid Leukemia (1) T-Cell Neoplasm (1) Myelofibrosis,MF (1) Waldenström Macroglobulinemia (1) Accelerated Phase Myeloproliferative Neoplasm (1) Prostate Cancer (1)

Modalities

small molecule (3)

Companies

GSK (1) Swedish Orphan Biovitrum (1) Theradex (1)

Related targets

JAK2 (3) FLT3 (2) IRAK1 (2) JAK1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.